Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain

Journal of Medical Microbiology

Volumn 60, Issue 11, 2011, Pages 1617-1625

  Woo, Timothy D H ^a   Oka, Kentaro ^b   Takahashi, Motomichi ^b   Hojo, Fuhito ^a   Osaki, Akako ^a   Hanawa, Tomoko ^a   Kurata, Satoshi ^a   Yonezawa, Hideo ^a   Kamiya, Shigeru ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Miyarisan Pharmaceutical Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CBM 588; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM DIFFICILE; COLITIS; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DETOXIFICATION; DIARRHEA; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM DIFFICILE; COCULTURE TECHNIQUES; ENTEROTOXINS; HUMANS; PROBIOTICS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, BACTERIAL; VERO CELLS;

EID: 80053516398     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.033423-0     Document Type: Article

References (44)

1. Banerjee, P., Merkel, G. J. & Bhunia, A. K. (2009). Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog 1, 8.
2. Borriello, S. P. & Barclay, F. E. (1986). An in-vitro model of colo nisation resistance to Clostridium difficile infection. J Med Microbiol 21, 299-309.
3. Boyle, R. J., Robins-Browne, R. M. & Tang, M. L. K. (2006). Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 83, 1256-1264, quiz 1446-1447.
4. Carter, G. P., Purdy, D., Williams, P. & Minton, N. P. (2005). Quorum sensing in Clostridium difficile: analysis of a luxS-type signalling system. J Med Microbiol 54, 119-127.
5. Castagliuolo, I., Riegler, M. F., Valenick, L., LaMont, J. T. & Pothoulakis, C. (1999). Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67, 302-307.
6. Chen, X., Kokkotou, E. G., Mustafa, N., Bhaskar, K. R., Sougioultzis, S., O'Brien, M., Pothoulakis, C. & Kelly, C. P. (2006). Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281, 24449-24454.
7. deVos, P., Garrity, G., Jones, D., Krieg, N. R., Ludwig, W., Rainey, F. A., Schleifer, K.-H. & Whitman, W. B. (editors) (2009). Bergey's Manual of Systematic Bacteriology, vol. 3. New York: Springer-Verlag.
8. Dingle, T., Mulvey, G. L., Humphries, R. M. & Armstrong, G. D. (2010). A real-time quantitative PCR assay for evaluating Clostridium difficile adherence to differentiated intestinal Caco-2 cells. J Med Microbiol 59, 920-924.
9. Engelbrektson, A., Korzenik, J. R., Pittler, A., Sanders, M. E., Klaenhammer, T. R., Leyer, G. & Kitts, C. L. (2009). Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol 58, 663-670.
10. Henrich, T. J., Krakower, D., Bitton, A. & Yokoe, D. S. (2009). Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 15, 415-422.
11. Huang, H., Weintraub, A., Fang, H. & Nord, C. E. (2009). Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 34, 516-522.
12. Hundsberger, T., Braun, V., Weidmann, M., Leukel, P., Sauerborn, M. & von Eichel-Streiber, C. (1997). Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem 244, 735-742.
13. Ichikawa, H., Kuroiwa, T., Inagaki, A., Shineha, R., Nishihira, T., Satomi, S. & Sakata, T. (1999). Probiotic bacteria stimulate gut epithelial cell proliferation in rat. Dig Dis Sci 44, 2119-2123.
14. Imase, K., Takahashi, M., Tanaka, A., Tokunaga, K., Sugano, H., Tanaka, M., Ishida, H., Kamiya, S. & Takahashi, S. (2008). Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. Microbiol Immunol 52, 156-161.
15. Kamiya, S., Taguchi, H., Yamaguchi, H., Osaki, T., Takahashi, M. & Nakamura, S. (1997). Bacterioprophylaxis using Clostridium butyricum for lethal caecitis by Clostridium difficile in gnotobiotic mice. Rev Med Microbiol 8 (Suppl. 1), S60.
16. Karlsson, S., Burman, L. G. & Akerlund, T. (1999). Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. Microbiology 145, 1683-1693.
17. Karlsson, S., Dupuy, B., Mukherjee, K., Norin, E., Burman, L. G. & Akerlund, T. (2003). Expression of Clostridium difficile toxins A and B and their sigma factor TcdD is controlled by temperature. Infect Immun 71, 1784-1793.
18. Kyne, L., Warny, M., Qamar, A. & Kelly, C. P. (2001). Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357, 189-193.
19. Lee, A. S. & Song, K. P. (2005). LuxS/autoinducer-2 quorum sensing molecule regulates transcriptional virulence gene expression in Clostridium difficile. Biochem Biophys Res Commun 335, 659-666.
20. Matsuki, T., Watanabe, K., Fujimoto, J., Kado, Y., Takada, T., Matsumoto, K. & Tanaka, R. (2004). Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria. Appl Environ Microbiol 70, 167-173.
21. McFarland, L. V. (2009). Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 15, 274-280.
22. McFarland, L. V. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16, 2202-2222.
23. McIntyre, A., Gibson, P. R. & Young, G. P. (1993). Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut 34, 386-391.
24. Nakamura, S., Nakashio, S., Inamatsu, T., Nishida, N., Taniguchi, N. & Nishida, S. (1980). Toxigenicity of Clostridium difficile isolates from patients and healthy adults. Microbiol Immunol 24, 995-997.
25. Nakamura, S., Mikawa, M., Tanabe, N., Yamakawa, K. & Nishida, S. (1982). Effect of clindamycin on cytotoxin production by Clostridium difficile. Microbiol Immunol 26, 985-992.
26. Nakanishi, S. & Tanaka, M. (2010). Sequence analysis of a bacteriocinogenic plasmid of Clostridium butyricum and expression of the bacteriocin gene in Escherichia coli. Anaerobe 16, 253-257.
27. Okamoto, T., Sasaki, M., Tsujikawa, T., Fujiyama, Y., Bamba, T. & Kusunoki, M. (2000). Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J Gastroenterol 35, 341-346.
28. Pépin, J., Valiquette, L., Alary, M. E., Villemure, P., Pelletier, A., Forget, K., Pépin, K. & Chouinard, D. (2004). Clostridium difficileassociated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171, 466-472.
29. Preidis, G. A. & Versalovic, J. (2009). Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136, 2015-2031.
30. Qa'Dan, M., Spyres, L. M. & Ballard, J. D. (2000). pH-induced conformational changes in Clostridium difficile toxin B. Infect Immun 68, 2470-2474.
31. Scharlau, D., Borowicki, A., Habermann, N., Hofmann, T., Klenow, S., Miene, C., Munjal, U., Stein, K. & Glei, M. (2009). Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res 682, 39-53.
32. Scheppach, W., Sommer, H., Kirchner, T., Paganelli, G. M., Bartram, P., Christl, S., Richter, F., Dusel, G. & Kasper, H. (1992). Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103, 51-56.
33. Segarra-Newnham, M. (2007). Probiotics for Clostridium difficileassociated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother 41, 1212-1221.
34. Seki, H., Shiohara, M., Matsumura, T., Miyagawa, N., Tanaka, M., Komiyama, A. & Kurata, S. (2003). Prevention of antibioticassociated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int 45, 86-90.
35. Takahashi, M., Taguchi, H., Yamaguchi, H., Osaki, T. & Kamiya, S. (2000). Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J Med Microbiol 49, 635-642.
36. Takahashi, M., Taguchi, H., Yamaguchi, H., Osaki, T., Komatsu, A. & Kamiya, S. (2004). The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157: H7 infection in mice. FEMS Immunol Med Microbiol 41, 219-226.
37. Tan, K. S., Wee, B. Y. & Song, K. P. (2001). Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J Med Microbiol 50, 613-619.
38. Trejo, F. M., Pérez, P. F. & De Antoni, G. L. (2010). Co-culture with potentially probiotic microorganisms antagonises virulence factors of Clostridium difficile in vitro. Antonie van Leeuwenhoek 98, 19-29.
39. Valenzuela-Martinez, C., Pena-Ramos, A., Juneja, V. K., Korasapati, N. R., Burson, D. E. & Thippareddi, H. (2010). Inhibition of Clostridium perfringens spore germination and outgrowth by buffered vinegar and lemon juice concentrate during chilling of ground turkey roast containing minimal ingredients. J Food Prot 73, 470-476.
40. Welch, A. R., Borriello, S. P. & Barclay, F. E. (1985). Simplified procedure for tissue culture in routine detection of cytotoxins. J Clin Pathol 38, 835-837.
41. Wilcox, M. H., Cunniffe, J. G., Trundle, C. & Redpath, C. (1996). Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 34, 23-30.
42. Wilson, M. (2005). Microbial Inhabitants of Humans: Their Ecology and Role in Health and Disease. Cambridge: Cambridge University Press
43. Yamakawa, K., Karasawa, T., Ohta, T., Hayashi, H. & Nakamura, S. (1998). Inhibition of enhanced toxin production by Clostridium difficile in biotin-limited conditions. J Med Microbiol 47, 767-771
44. Yamamoto-Osaki, T., Kamiya, S., Sawamura, S., Kai, M. & Ozawa, A. (1994). Growth inhibition of Clostridium difficile by intestinal flora of infant faeces in continuous flow culture. J Med Microbiol 40, 179-187